Status:

COMPLETED

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

Lead Sponsor:

Johns Hopkins University

Collaborating Sponsors:

GlaxoSmithKline

Conditions:

Deep Venous Thrombosis

Pulmonary Embolism

Eligibility:

All Genders

18-70 years

Phase:

EARLY_PHASE1

Brief Summary

This pilot study is designed to determine the feasibility of conducting a randomized clinical trial comparing fondaparinux sodium (Arixtra) once daily with enoxaparin (Lovenox®) twice daily with respe...

Detailed Description

In order to determine the feasibility of such a trial we need to determine the necessary sample size. In order to determine the necessary sample size, we need to obtain estimates of the incidence of D...

Eligibility Criteria

Inclusion

  • Men or women 18 years or older.
  • Body mass index (BMI) of 35kg/m2 or greater.
  • Undergoing laparoscopic bariatric surgery, i.e., laparoscopic sleeve gastrectomy, laparoscopic Roux-en Y gastric bypass or laparoscopic duodenal switch.

Exclusion

  • History of previous deep vein thrombosis.
  • History of previous pulmonary emboli.
  • History of documented clotting/coagulation disorder.
  • History of cancer.
  • Weight \< 50 kg or \> 200 kg or unable to fit in MRI scanner.
  • Presence of metallic foreign bodies
  • Recent history of smoking (within the last year).
  • History of venous stasis disease.
  • History of obesity hypoventilation syndrome.
  • Patients who are unable to lay flat for extended periods of time or are claustrophobic.
  • Patients who have a pacemaker, an implanted defibrillator or certain other implanted or electronic or metallic devices (implanted medical or metallic devices, shrapnel, or metal).
  • History of hypersensitivity reaction to anticoagulation products.
  • History of HIT (Heparin Induced Thrombocytopenia.
  • History of Renal Insufficiency (Creatinine Clearance \< 50).
  • Active clinically significant bleeding.
  • Acute bacterial endocarditis.
  • BMI \> 60.
  • Patients with metallic foreign body or implant (unable to have an MRV study).

Key Trial Info

Start Date :

June 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2013

Estimated Enrollment :

198 Patients enrolled

Trial Details

Trial ID

NCT00894283

Start Date

June 1 2009

End Date

September 1 2013

Last Update

June 7 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States, 21224

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients | DecenTrialz